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ABSTRACT
Diabetology and rheumatology have much in common, including many biochemical features. Diabetic 
cases suffer excessively from common musculoskeletal conditions. The present study aimed to explore the 
association between the caffeic acid phenethyl ester (CAPE) treatment and the standard parameters of diabetic 
and rheumatologic controls. Serum anti-streptolysin-O (ASO), C-reactive protein (CRP), rheumatoid factor 
(RF) titers and glucose (GLU), cholesterol (CHOL), triglyceride (TG), high density lipoprotein (HDL), very low 
density lipoprotein (VLDL), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), sodium (Na), 
potassium (K), chloride (Cl), calcium (Ca), phosphorus (P), uric acid (UA), iron (Fe), iron-binding capacity 
(IBC), total iron-binding capacity (TIBC) and superoxide dismutase (SOD) levels were measured in 22 female 
Wistar-Albino rats. The animals were divided into three groups: group 1: non-diabetic rats as control; group 2: 
streptozotocin (STZ)-induced, untreated diabetic rats; and group 3: STZ-induced, CAPE-treated diabetic rats. 
Levels of GLU were increased in group 2. ASO values were decreased in group 3. TG and VLDL levels were 
increased in group 3 compared with the group 1. Higher UA levels were detected in group 3 compared with 
group 2. The levels of Fe and TIBC were decreased in group 3. The results of the present study indicate the 
reducing effect of CAPE on the serum levels of diabetic and rheumatologic parameters in diabetic rats.
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Introduction 
Caffeic acid phenethyl ester (CAPE), a fl avonoid-like compound, is one of the major 
components of honeybee propolis. CAPE, which has no reported harmful effects on 
normal cells (ILHAN et al., 1999), has several biological and pharmacological properties: 
antioxidant (SUD’INA et al., 1993), anti-infl ammatory (MICHALUART et al., 1999), anti-
carcinogenic (CHEN et al., 2001), antiviral (FESEN et al., 1994), and immunomodulatory 
(PARK and KAHNG, 1999) activities.
In previous studies CAPE has been suggested as an agent that signifi cantly lowers 
hyperglycemia and reverses some diabetic complications in rat models, with both 
streptozotocin (STZ)-induced diabetes type 1 (JUNG et al., 2006) and type 2 (PARK and 
MIN, 2006). As such, it is stated that CAPE treatment should be considered in treating 
hyperglycemia and liver complications in diabetic patients (CELIK et al., 2009). 
Recent scientifi c evidence has revealed unsuspected infl uences between iron 
metabolism and diabetes. The correlation is bi-directional—iron affects glucose 
metabolism, and glucose metabolism impinges on various iron metabolic pathways. 
Oxidative stress and infl ammatory factors infl uence these relationships, amplifying and 
potentiating the initiated events (FERNÁNDEZ-REAL et al., 2002).
Likewise, diabetology and rheumatology are two medical specializations that have 
much in common, including many immuno-chemical features. Diabetes affects the 
connective tissues and causes alterations in the peri-articular and the musculo-skeletal 
systems. The biochemical mechanisms for some of these conditions have not been 
understood completely (CAGLIERO, 2003).
To the best of our knowledge, there have been no experimental studies regarding the 
effects of caffeic acid phenethylester on rheumatologic parameters and iron metabolism 
in STZ-induced diabetic rats. Hence, the present study was designed to investigate the 
possible effects of CAPE on iron metabolism and rheumatologic parameters in diabetic 
rats. We evaluated anti-streptolysin-O (ASO), C-reactive protein (CRP) and rheumatoid 
factor (RF) titers, as well as iron (Fe), iron-binding capacity (IBC), total iron-binding 
capacity (TIBC) levels. This study also investigated the effects of CAPE on antioxidant 
defense, serum lipids, electrolytes and liver enzymes affected by diabetes. 
Materials and methods
Animals and diets. Twenty-six female Wistar-Albino rats (11 weeks old and 223.5 ± 
41.8 body weight) were used in the study. They were kept in an environment of controlled 
temperature (24-26 °C), humidity (55-60 %), and controlled photoperiod (12 h light/dark 
cycle) during the experiment. The animals were fed a commercial balanced diet based on 
corn, wheat, soybean meal, hazelnut meal, meat-bone meal, and fi sh meal. The chemical 
composition of the diet was: dried matter 88 %, crude protein 23 %, crude cellulose 7 %, 
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crude ash 8 %, Ca 1-2.8 %, NaCl 1 %, metabolizable energy 2.600 Kcal/kg, and vitamin 
A 400 IU/kg. Diet and tap water were provided ad libitum. The experimental procedures 
were approved by Mustafa Kemal University, Veterinary Faculty Ethics Committee for 
the use and care of laboratory animals.
Induction of diabetes, CAPE treatments, and sample collection. Animals were 
randomly divided into three groups (each animal placed separately in a stainless-steel 
cage) as follows: group 1, non-diabetic control rats (n = 6); group 2, STZ-induced, 
untreated diabetic rats (n = 10); and group 3, STZ-induced, CAPE-treated diabetic rats 
(n = 10), which were injected daily with caffeic acid phenethyl ester (CAPE). CAPE 
was commercially purchased (Sigma Chemical Co., St. Louis, MO, USA, C8221) and 
administered intraperitoneally (i.p.) at a dose of 10 μmol/mL/kg/day 3 days after STZ 
application, and the treatment was continued for 60 days. 
STZ (Sigma Chemical Co., St. Louis, MO, USA, S0130) dissolved in sodium citrate 
buffer (pH 4.5) and administered i.p. at a single dose of 50 mg/kg body mass. Isotonic 
saline solution (an equal volume) was injected (i.p.) into the control rats. Blood glucose 
(B-GLU) levels were measured with an Accu-Chek Active strip test in a glucometer 
(Roche Diagnostic, Mannheim, Germany) in all rats after 3 days of STZ treatment. A 
total of 4 animals from group 2 were excluded from the study during the experimental 
applications. Two of them were excluded due to health deterioration and the others had 
B-GLU levels less than 300 mg/dL. 
At the end of the experimental period, blood samples were taken from the tail vein of 
the anaesthetized animals (50 mg/kg ketamin hydrochloride, i.m.). All blood tubes were 
centrifuged at 825× g at 4 oC for 10 min to obtain the serum. The serum samples were 
immediately stored at -25 oC until biochemical assays.
Biochemical analyses. Serum samples were used for analyses of glucose (GLU), 
cholesterol (CHOL), triglyceride (TG), high density lipoprotein (HDL), very low density 
lipoprotein (VLDL), calcium (Ca), sodium (Na), potassium (K), chloride (Cl), phosphorus 
(P), uric acid (UA), iron (Fe), iron-binding capacity (IBC), total iron-binding capacity 
(TIBC), C-reactive protein (CRP), anti-streptolysin O (ASO) and rheumatoid factor (RF), 
as well as gamma glutamyl transferase (GGT) and alkaline phosphatase (ALP) activities, 
using commercially available kits (Roche Diagnostics GmbH; Mannheim, Germany) in 
an auto-analyzer (Cobas Integra 800; Roche Diagnostics GmbH; Mannheim, Germany). 
Superoxide dismutase (SOD) activities were analyzed using commercially available kits 
(OxiSelect SOD Activity Assay, Cell Biolabs, STA-340, USA). 
Statistical analyses. The MINITAB® 16.1 program (Minitab Inc., USA) was used 
for the statistical analyses and the confi dence interval was determined as 95 %. One-way 
analysis of variance was used to compare the mean values of the results of biochemical 
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analyses among the animals in all study groups. Tukey’s test was used for posthoc 
comparisons when indicated by a signifi cant F-test for a group.
Results
The GLU level in the serum was increased in the untreated diabetic rats compared 
with the rats of the control and CAPE-treated diabetics groups, indicating that CAPE 
treatment signifi cantly (P<0.05) reduced serum GLU levels, even below the control level 
compared with the untreated-diabetic group (Table 1).
Table 1. Serum biochemical values (mean ± standard error) in control (group 1, n = 6), diabetic 





P value1 2 3
GLU (mg/dL) 160.83 ± 18.73b 373.67 ± 114.54a 145.60 ± 39.65b < 0.05
CHOL (mg/dL) 71.33 ± 5.72 78.00 ± 14.70 63.50 ± 16.05 NS
TG (mg/dL) 82.83 ± 38.34b 124.83 ± 63.73ab 225.70 ± 131.75a < 0.05
HDL (mg/dL) 40.33 ± 12.99 34.17 ± 27.04 18.00 ± 14.30 NS
VLDL (mg/dL) 17.67 ± 7.79b 24.83 ± 12.72ab 45.10 ± 26.40a < 0.05
ALP (IU/L) 202.5 ± 42.2 295.2 ± 186.6 278.9 ± 106.1 NS
GGT (IU/L) 2 ± 0.632 7.167 ± 5.456 7.3 ± 8.220 NS
Na (mmol/L) 152.37 ± 4.06 148.88 ± 6.39 148.90 ± 3.20 NS
K (mmol/L) 5.3317 ± 0.6972 5.1150 ± 0.77 5.6930 ± 0.5158 NS
Cl (mmol/L) 103.16 ± 1.78 101.35 ± 5.32 104.23 ± 3.70 NS
Ca (mg/dL) 11.55 ± 0.418 11.8 ± 0.469 11.26 ± 0.860 NS
P (mg/dL) 4.3 ± 1.030 4.367 ± 1.686 4.9 ± 1.719 NS
UA (mg/dL) 1.5 ± 0.3742ab 1.1333 ± 0.1633b 1.73 ± 0.4398a < 0.05
Fe (μg/dL) 259.21 ± 34.67a 181.42 ± 81.10ab 136.94 ± 77.14b < 0.05
IBC (μg/dL) 409.2 ± 156.8 523.5 ± 147.1 360.1 ± 108.6 NS
TIBC (μg/dL) 643 ± 133.52a 705.17 ± 96.35a 503.90 ± 59.94b < 0.05
SOD (inhibition %) 0.23333 ± 0.03445 0.22833 ± 0.04262 0.17620 ± 0.07323 NS
ASO (IU/mL) 37.50 ± 13.33a 23.12 ± 8.22ab 18.84 ± 13.68b < 0.05
CRP (IU/mL) 0.01583 ± 0.01429 0.025 ± 0.03886 0.002 ± 0.00632 NS
RF (IU/mL) 8.317 ± 0.752 9.267 ± 3.757 8.710 ± 7.530 NS
Different superscripts a,b in the same row indicate signifi cant differences among group (P<0.05). GLU: Glucose; 
CHOL: Cholesterol; TG: Triglyceride; HDL: High density lipoprotein; VLDL: Very low density lipoprotein; 
ALP: Alkaline phosphatase; GGT: Gamma-glutamyl transferase; Na: Sodium; K: Potassium; Cl: Chloride; 
Ca: Calcium; P: Phosphorus; UA: Uric acid; Fe: Iron; IBC: Iron-binding capacity; TIBC: Total iron-binding 
capacity; SOD: Superoxide dismutase; ASO: Anti-streptolysin-O; CRP: C-reactive protein; RF: Rheumatoid 
factor; NS: not signifi cant. 
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In the CAPE-treated diabetic group, the TG levels were higher than those of the 
control group. The TG level was increased signifi cantly by the CAPE treatment in 
diabetic rats compared with the control rats (P<0.05). Similarly, the level of VLDL was 
increased in the group of CAPE-treated diabetic rats compared with the rats of the control 
group. Other lipid markers (CHOL and LDL) evaluated in the present study decreased 
insignifi cantly in the CAPE-treated diabetic rats compared to controls and untreated 
diabetics. On the other hand, liver enzyme (ALP and GGT) activities increased in the 
diabetic rats (both groups 2 and 3), compared with the control group. However these 
results were not statistically signifi cant.
Higher UA levels were detected in the CAPE-treated diabetic group compared with 
the untreated diabetics (P<0.05). CAPE did not signifi cantly affect the Na, K, Cl, Ca and 
P concentrations. However, the CAPE treatment signifi cantly reduced the levels of Fe 
parameters below that of other groups. In the CAPE-treated diabetic group, Fe (P<0.05) 
and TIBC (P<0.05) were signifi cantly lower. SOD activity was insignifi cantly decreased 
in the CAPE-treated diabetic rats, compared with the other groups.
Levels of rheumatologic markers (ASO, CRP and RF) were decreased in the CAPE-
treated diabetic group compared to the diabetic group, but with no statistically signifi cant 
difference, with the exception of ASO. CAPE treatment reduced ASO levels signifi cantly 
(P<0.05) compared to the control group.
Discussion
To the best of our knowledge, the present study is the fi rst report on the effects of 
CAPE on Fe metabolism and rheumatologic parameters in STZ-induced diabetic rats. 
Our results demonstrate lower levels of Fe parameters and rheumatologic markers in the 
CAPE administered diabetic group. 
Fe is one of the essential elements required for a variety of molecules to maintain 
their normal structure and functions, and for cells to live, grow, and proliferate. The 
homeostasis of Fe results from tightly coordinated regulation by various proteins involved 
in uptake, excretion and intracellular storage/traffi cking (LIU et al., 2009). In the present 
study, CAPE treatment signifi cantly reduced the levels of Fe (P<0.05) and TIBC (P<0.05) 
below those of the non-diabetic control and untreated diabetic groups. Although there 
has been no such study regarding the levels of Fe parameters in CAPE-treatment, there 
is a report investigating the protective effect of CAPE on oxidative damage due to Fe 
overload in rats (CÜRE, 2007). In that study, ferritin was signifi cantly elevated in the Fe 
and CAPE+Fe groups. The ferritin level is specifi ed as a marker that refl ects the amount 
of Fe stored, and it acts as a buffer against Fe defi ciency and Fe overload. This diversity 
from our results may be caused by the differences between the designs (Fe overload or 
diabetes inductions) of the experiments. On the other hand, CÜRE (2007) reported that 
CAPE may be an effective treatment option for protection from Fe induced oxidative 
stress in heart and liver tissues.
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In another study investigating the effects of CAPE on Fe-induced liver damage, it is 
reported that CAPE treatment prevented the increase in myeloperoxidase (MPO) activity 
and malondialdehyde (MDA) levels and it is suggest that CAPE may be an available 
agent to protect the liver from injury via inhibition of MPO activity (OKTAR et al., 2009). 
Considering this, it may be proposed that the decreasing effect of CAPE on Fe levels may 
help to support acute stress responses and a healthy antioxidant system. 
Diabetes has major effects on connective tissues, which have a signifi cant impact on 
both the development and outcome of diseases of cartilage, bones, ligaments, and tendons. 
An improved understanding of the mechanisms through which diabetes alters connective 
tissue metabolism should lead to better preventive and therapeutic interventions. In the 
present study, levels of rheumatologic markers (ASO, CRP and RF) were decreased in the 
CAPE-treated diabetic group. CAPE treatment reduced the levels of ASO signifi cantly 
compared to the controls. However, as there has been no study to compare the present 
fi ndings it was not possible to further evaluate our results. However, our results could 
establish a base for future clinical or experimental rheumatologic studies, and incremental 
progress can be made in understanding the interactions between diabetes and common 
musculoskeletal syndromes and the role of CAPE in the treatment. 
As for biochemical fi ndings in the present study, CAPE treatment signifi cantly 
(P<0.05) reduced serum GLU levels, even below the control levels, compared with the 
untreated-diabetic group. Parallel to previous studies (JUNG et al., 2006; CELIK et al., 
2009; ABDULJAWAD et al., 2013) we can suggest the signifi cant potential of CAPE as an 
antidiabetic agent. Between the investigated lipid parameters, CHOL and HDL showed 
insignifi cant decreases in the CAPE treatment group. However, we could not fi nd lower 
levels of TG, VLDL and UA, which were expected to decrease by CAPE treatment 
(CELIK et al., 2009; YOSHIZUMI et al., 2005). However this deviation from other studies 
may result from the animal types, different formulations, and application routes of CAPE 
treatments. Furthermore, regarding the biochemical mechanism linking increased uric 
acid to decreased iron, the pathway is currently unclear. Uric acid is associated with 
infl ammation, but it also acts as a powerful endogenous antioxidant (AMES et al., 1981). 
This has led some to contend that increased uric acid could be protective by blocking 
oxidative stress. However, this theory needs to be investigated. 
Increased levels of triglycerides and reduced HDL concentrations are key 
characteristics of dyslipidemia in diabetes (SYVÄNNE and TASKINEN, 1999). Besides, 
lower cholesterol and higher triglyceride levels were reported in a study when iron was 
associated with diabetes (SILVA et al., 2011). Here, in our study, we observed changes 
in the levels of these lipid metabolites, probably due to the effects of reduced insulin 
secretion and CAPE.
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It is concluded that the measurement of biochemical parameters, Fe metabolites and 
rheumatologic markers may help to explain the mechanism of the therapeutic effects of 
CAPE. In the present study, CAPE treatment signifi cantly reduced the levels of ASO in 
the CAPE-treated diabetic group. In this regard CAPE treatment (LIU et al., 2013; GUREL 
et al., 2004; WEI et al., 2004) might also play a potential therapeutic role in rheumatic 
diseases. Iron is a fi rst-line prooxidant and it contributes to the regulation of the clinical 
appearances of numerous systemic diseases, including diabetes. Iron regulation of cell 
oxidative stress may explain, at least in part, its close association with abnormalities in 
insulin sensitivity (FERNÁNDEZ-REAL et al., 2002). Consequently, further studies must 
be conducted in order to explore the biochemical mechanisms of the reducing effect of 
CAPE on the serum values of Fe and rheumatologic markers, and improve the ability to 
predict and prevent metabolic problems. 
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SAŽETAK
Dijabetologija i reumatologija imaju mnoge sličnosti, uključujući biokemijske procese. Oboljeli od 
dijabetesa pate od teških stanja mišićno-koštanog sustava. U ovom radu istražena je povezanost između liječenja 
fenetil esterom kavene kiseline i standardnih pokazatelja koji se kontroliraju pri dijabetičnim i reumatoidnim 
bolestima. Kod 22 Wistar-Albino štakorice mjereni su: serumski anti-streptolizin-O (ASO), C-reaktivni protein 
(CRP), titar reumatoidnog faktora (RF), zatim razina glukoze (GLU), kolesterola (CHOL), triglicerida (TG), 
lipoproteina visoke gustoće (HDL), lipoproteina vrlo niske gustoće (VLDL), alkalne fosfataze (ALP), gama-
glutamil transferaze (GGT), natrija (Na), kalija (K), klorida (Cl), kalcija (Ca), fosfora (P), mokraćne kiseline 
(UA), željeza (Fe), kapaciteta vezanja željeza (IBC), ukupnog kapaciteta vezanja željeza (TIBC) i superoksid 
dismutaze (SOD). Životinje su bile podijeljene u tri skupine: 1. štakorice bez dijabetesa (kontrolna skupina), 
2. neliječene štakorice s dijabetesom izazvanim streptozotocinom (STZ) i 3. štakorice sa streptozotocin (STZ) 
- izazvanim dijabetesom liječenim fenetil esterom kavene kiseline. Razine GLU bile su povećane u skupini 
2. ASO vrijednosti bile su snižene u skupini 3. Razine TG i VLDL bile su povišene u skupini 3 u usporedbi s 
razinama u skupini 1. Više razine UA utvrđene su u skupini 3 u usporedbi sa skupinom 2. Razine Fe i TIBC 
bile su snižene u skupini 3. Rezultati pokazuju reducirajuće učinke fenetil estera kavene kiseline na razinu 
dijabetičnih i reumatoloških pokazatelja u serumu štakorica sa šećernom bolešću izazvanom streptozotocinom.
 Ključne riječi: fenetil ester kavene kiseline, dijabetes, željezo, štakor, reumatološki pokazatelji ________________________________________________________________________________________
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